4SC: Landmark RESMAIN study data presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting

Maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change current clinical practice
  • RESMAIN is one of the largest clinical trials in cutaneous T-cell lymphoma (CTCL) to-date
  • Resminostat (Kinselby) as a maintenance treatment for advanced CTCL, is clinically proven to postpone disease progression in patients – a new treatment paradigm in CTCL
    • Resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95%CI: 0.424, 0.916)
    • Resminostat (Kinselby)’s median time to next treatment (median TTNT) versus placebo showed a significant improvement, more than doubling to 8.8 months compared to 4.2 months; p= 0.002; HR: 594 (95% CI: 0.424, 0.916)
    • The side effects of resminostat were mainly mild to moderate, manageable and reversible

Read more here…